Top Markets
Coin of the day
NeuBase Therapeutics, Inc. NeuBase Therapeutics, Inc.

NeuBase Therapeutics, Inc.

NBSE
Peringkat dalam Saham #39173
Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics,... Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics, Inc. is dedicated to pioneering therapeutic solutions for rare genetic disorders and various cancers stemming from aberrant genes. At the core of its approach is the proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform. This technology is being utilized to target ailments such as Huntington's disease (HD) and myotonic dystrophy, in addition to a broader spectrum of genetic conditions and applications within oncology. The company's leading therapeutic candidates encompass NT0100, a PATrOL-powered anti-gene therapy for Huntington's disease; NT0200, another PATrOL-enabled anti-gene solution for myotonic dystrophy type 1; and NT0300, a PATrOL-based treatment specifically engineered to address the mutated KRAS gene. NeuBase Therapeutics, Inc. maintains its headquarters in Pittsburgh, Pennsylvania.
Harga Saham
$0.378
Terakhir disinkronkan: 2024-05-24
Kapitalisasi Pasar
$618.41K
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan NeuBase Therapeutics, Inc. (NBSE)

Kategori

Riwayat harga saham NeuBase Therapeutics, Inc. (NBSE)
Harga penutupan tertinggi: $0.39 pada 2024-05-01

Harga penutupan terendah: $733.33 pada 2004-05-01
Riwayat harga saham NeuBase Therapeutics, Inc. dari 2004 hingga 2026
Performa harga saham tahunan
Tahun Performa
2024 -49.90%
2023 -81.22%
2022 -92.72%
2021 -64.02%
2020 7.86%
2019 205.09%
2018 -92.38%
2017 -19.09%
2016 -60.75%
2015 75.31%
2014 6.31%
2013 49.44%
2012 167.16%
2011 169.72%
2010 -59.63%
2009 129.24%
2008 14.29%
2007 -48.15%
2006 -74.29%
2005 -15.32%
2004 0.00%
Harga saham perusahaan atau pesaing serupa
Perusahaan Harga saham Perubahan 1th% Negara
$517.18 32.51%
US
$857.76 31.47%
NL
$731.95 7.17%
CH
$1.07K -6.40%
KR
$257.04 13.55%
BE